Cost Effectiveness and Payment Policy

Handbook of Health Economics

Volumn 2, Issue , 2011, Pages 471-497

  Garber, Alan M ^a   Sculpher, Mark J ^b  

^a University of York ^*  (United States)

^b UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Cost effectiveness analysis; Cost benefit analysis; Decision making; Health policy

Indexed keywords

EID: 83255192326     PISSN: 15740064     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-53592-4.00008-6     Document Type: Chapter

References (72)

1. Baker R., Bateman I., Donaldson C. Weighting and valuing quality adjusted life years: Preliminary results from the Social Value of a QALY Project 2008, National Institute for Health and Clinical Excellence, London, Final Report to NICE.
2. Baltussen, R. & Niessen, L. (2006). Priority setting of health interventions: The need for multi-criteria decision analysis. Cost Effectiveness and Resource Allocation, 4. 10.1186/478-7547-4-14.
3. Briggs A., Claxton K., Sculpher M. Decision modelling for health economic evaluation 2006, Oxford University Press, Oxford.
4. Brouwer W.B.F., Rutten F.F.H. The efficiency frontier approach to economic evaluation: Will it help German policy making?. Health Economics 2010, 19:1128-1131.
5. Brouwer W.B.F., Culyer A.J., van Exel N., Rutten F.F.H. Welfarism vs. extra-welfarism. Journal of Health Economics 2008, 27(2):325-338.
6. Carlson J.J., Sullivan S.D., Garrison L.P., Neumann P.J., Veenstra D.L. Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy 2010, 96(3):179-190.
7. Caro J., Nord E., Siebert U., McGuire A., McGregor M., Henry D., et al. The efficiency frontier approach to economic evaluation of health-care interventions. Health Economics 2010, 10.1002/hec.1629.
8. Chalkidou K., Hoy A., Littlejohns P. Making a decision to wait for more evidence: When the National Institute for Health and Clinical Excellence recommends a technology only in the context of research. Journal of the Royal Society of Medicine 2007, 100(10):453.
9. Chalkidou K., Lord J., Fischer A., Littlejohns P. Evidence-based decision making: When should we wait for more information?. Health Affairs (Project Hope) 2008, 27(6):1642.
10. Chernew M., Rosen A., Fendrick A. Value-based insurance design. Health Affairs 2007, 26(2):w195.
11. Claxton K. OFT, VBP: QED?. Health Economics 2007, 16(6):545-558.
12. Claxton K., Sculpher M.J. Using value of information analysis to prioritise health research: Some lessons from recent UK experience. PharmacoEconomics 2006, 24:1055-1068.
13. Claxton K., Briggs A., Buxton M.J., Culyer A.J., McCabe C., Walker S., et al. Value based pricing for NHS drugs: An opportunity not to be missed?. British Medical Journal 2008, 336(7638):251-254.
14. Claxton K., Sculpher M., Carroll S. Value based pricing for pharmaceuticals: Its role, specification and prospects in a newly devolved NHS 2011, University of York, York, Contract No.: 60.
15. Claxton K., Sculpher M., McCabe C., Briggs A., Akehurst R., Buxton M., et al. Probabilistic sensitivity analysis for NICE technology assessment: Not an optional extra. Health Economics 2005, 14:339-347.
16. Claxton K., Sculpher M.J., Culyer A.J., McCabe C., Briggs A.H., Akehurst R., et al. Discounting and cost-effectiveness in NICE-stepping back to sort out the confusion. Health Economics 2006, 15:1-4.
17. Culyer A., McCabe C., Briggs A., Claxton K., Buxton M., Akehurst R., et al. Searching for a threshold, not setting one: The role of the National Institute for Health and Clinical Excellence. Journal of Health Services Research & Policy 2007, 12(1):56.
18. Culyer A.J. Deliberative processes in decisions about health care technologies: Combining different types of evidence, values, algorithms and people 2009, Office of Health Economics, London.
19. Department of Health A new value-based approach to the pricing of branded medicines 2010, Department of Health, London, UK, Available from: .
20. De Pouvourville, G. (2009). Pricing and reimbursment for drugs in France. What is the role for cost-effectiveness analysis? ESSEC Business School Working Paper. Paris.
21. Devlin N., Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Economics 2004, 13(5):437-452.
22. Dolan P. The measurement of individual utility and social welfare. Journal of Health Economics 1998, 17:39-52.
23. Dolan P., Edlin R., Tsuchiya A., et al. The relative societal value of health gains to different beneficiaries 2008, National Institute for Health and Clinical Excellence, London, Final Report to NICE.
24. Dolan P., Gudex C., Kind P., Williams A. Valuing health states: A comparison of methods. Journal of Health Economics 1996, 15:209-231.
25. Drummond M., Sculpher M., Torrance G., O'Brien B., Stoddart G. Methods for the economic evaluation of health care programmes 2005, Oxford University Press, USA, New York.
26. Fishman A., Martinez F., Naunheim K., Piantadosi S., Wise R., Ries A., et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. New England Journal of Medicine 2003, 348(21):2059.
27. Freemantle N., Hill S. Evaluating pharmaceuticals for health policy and reimbursement 2004, Blackwell, Oxford.
28. Gafni A., Birch S. QALYs and HYEs (healthy years equivalent). Spotting the differences. Journal of Health Economics 1997, 16(5):601-608.
29. Garber A., Jones C., Romer P. Insurance and incentives for medical innovation. Forum for Health Economics and Policy 2006, 9(2):4.
30. Garber A., Weinstein M., Torrance G., Kamlet M. Theoretical foundations of cost-effectiveness analysis. Cost-effectiveness in health and medicine 1996, 25-53. Oxford University Press, New York. M. Gold, J. Siegel, L. Russell, M. Weinstein (Eds.).
31. Garber A.M. Advances in cost-effectiveness analysis of health interventions. Handbook of health economics 2000, 181-221. North-Holland, Amsterdam. J.P. Newhouse, A.J. Culyer (Eds.).
32. Garber A.M. Evidence-based coverage policy. Health Affairs (Millwood) 2001, 20(5):62-82.
33. Garber, A. M. (2004). Cost-effectiveness and evidence evaluation as criteria for coverage policy. Health Affairs (Millwood), Suppl. Web Exclusives: W4-284-96.
34. Garber A.M., McClellan M.B. Satisfaction guaranteed-"payment by results" for biologic agents. New England Journal of Medicine 2007, 357(16):1575-1577.
35. Garber A.M., Phelps C.E. Economic foundations of cost-effectiveness analysis. Journal of Health Economics 1997, 16(1):1-31.
36. Garber A.M., Skinner J. Is American health care uniquely inefficient?. Journal of Economic Perspectives 2008, 22(4):27-50.
37. Garrison L.P. On the benefits of modeling using QALYs for societal resource allocation: The model is the message. Value in Health 2009, 12:S36-S37.
38. Glick H.A., Doshi J.A., Sonnad S.S., Polsky D. Economic evaluation in clinical trials 2007, Oxford University Press, Oxford.
39. Gold M., Stevenson D., Fryback D. HALY S and QALY S and DALY S, OHMY: Similarities and differences in summary measures of population health. Annual Review of Public Health 2002, 23(1):115-134.
40. Cost-effectiveness in health and medicine 1996, Oxford University Press, New York. M.R. Gold, J.E. Siegel, L.B. Russell, M.C. Weinstein (Eds.).
41. Hall R., Jones C. The value of life and the rise in health spending. Quarterly Journal of Economics 2007, 122(1):39-72.
42. Hatziandreu E., Koplan J., Weinstein M., Caspersen C., Warner K. A cost-effectiveness analysis of exercise as a health promotion activity. American Journal of Public Health 1988, 78(11):1417.
43. Henry D., Hill S., Harris A. Drug prices and value for money: The Australian Pharmaceutical Benefits Scheme. JAMA 2005, 294(20):2630.
44. Jena A., Philipson T. Cost-effectiveness analysis and innovation. Journal of Health Economics 2008, 27(5):1224-1236.
45. Johannesson M., Jönsson B. Economic evaluation in health care: Is there a role for cost-benefit analysis?. Health Policy 1991, 17(1):1-23.
46. Jonsson B. IQWiG: An opportunity lost. European Journal of Health Economics 2008, 9:205-207.
47. Kristensen F.B., Mäkelä M., Neikter S.A., Rehnqvist N., Håheim L.L., Mørland B., et al. European network for Health Technology Assessment, EUnetHTA: Planning, development, and implementation of a sustainable European network for Health Technology Assessment. International Journal of Technology Assessment in Health Care 2009, 25(Supplement S2):107-116.
48. Lakdawalla D., Sood N. Innovation and the welfare effects of public drug insurance. Journal of Public Economics 2009, 93(3-4):541-548.
49. Laupacis A. Incorporating economic evaluations into decision-making: The Ontario experience. Medical Care 2005, 43(7). II-15-II-19.
50. Levin L., Goeree R., Sikich N., Jorgensen B., Brouwers M., Easty T., et al. Establishing a comprehensive continuum from an evidentiary base to policy development for health technologies: The Ontario experience. International Journal of Technology Assessment in Health Care 2007, 23(3):299-309.
51. McCabe C., Claxton K., Culyer A. The NICE cost-effectiveness threshold: What it is and what that means. PharmacoEconomics 2008, 26(9):733-744.
52. Mehrez A., Gafni A. Quality-adjusted life years, utility theory, and healthy-years equivalents. Medical Decision Making 1989, 9:142-149.
53. Mishan E.J. Cost-benefit analysis 1988, Unwin Hyman, London.
54. Murray C., Acharya A. Understanding DALYs. Journal of Health Economics 1997, 16(6):703-730.
55. National Emphysema Treatment Trial Research Group (NETT) Rationale and design of the national emphysema treatment trial (NETT): A prospective randomized trial of lung volume reduction surgery. Journal of Thoracic and Cardiovascular Surgery 1999, 118(3):518-528.
56. National Institute for Health and Clinical Excellence (NICE) Guide to the methods of technology appraisal 2008, NICE, London.
57. National Institute for Health and Clinical Excellence (UK) (2009). Appraising life-extending, end of life treatments [cited November 2, 2010]. Available from: http://www.nice.org.uk/media/E4A/79/SupplementaryAdviceTACEoL.pdf/.
58. Naunheim K., Wood D., Mohsenifar Z., Sternberg A., Criner G., DeCamp M., et al. Long-term follow-up of patients receiving lung-volume-reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research Group. Annals of Thoracic Surgery 2006, 82(2):431-443.
59. O'Brien B.J., Drummond M.F., Labelle R.J., Willan A. In search of power and significance: Issues in the design and analysis of stochastic cost-effectiveness studies in health care. Medical Care 1994, 32(2):150-163.
60. Office of Fair Trading The pharmaceutical price regulation scheme. An OFT market study 2007, OFT, London.
61. O'Hagan A., Luce B. A primer on Bayesian statistics in health economics and outcomes research 2003, Medtap International, Bethesda, Maryland.
62. Phelps C.E., Mushlin A.I. On the (near) equivalence of cost effectiveness and cost benefit analysis. International Journal of Technology Assessment in Health Care 1991, 7(1):12-21.
63. Rawlins M. In pursuit of quality: The National Institute for Clinical Excellence. The Lancet 1999, 353(9158):1079-1082.
64. Sculpher M., Claxton K. Sins of omission and obfuscation: IQWIG's guidelines on economic evaluation methods. Health Economics 2010, 19:1132-1136.
65. Sculpher M., Drummond M. Analysis sans frontières: Can we ever make economic evaluations generalisable across jurisdictions?. PharmacoEconomics 2006, 24(11):1087-1099.
66. Stinnett A.A., Mullahy J. Net health benefits: A new framework for the analysis of uncertainty in cost-effectiveness analysis. Medical Decision Making 1998, 18(2 Suppl.):S68-S80.
67. Tarn T.Y., Smith M.D. Pharmacoeconomic guidelines around the world. ISPOR Connections 2004, 10(4):5.
68. Thaler R., Rosen S. The value of saving a life: Evidence from the labor market. Household production and consumption 1976, 265-298. National Bureau of Economic Research, Inc., New York. N.E. Terleckyj (Ed.).
69. Tunis S., Pearson S. Coverage options for promising technologies: Medicare's coverage with evidence development. Health Affairs 2006, 25(5):1218.
70. Viscusi W. The value of risks to life and health. Journal of Economic Literature 1993, 31(4):1912-1946.
71. Weinstein M.C., Stason W.B. Foundations of cost-effectiveness analysis for health and medical practices. New England Journal of Medicine 1977, 296(13):716-721.
72. Wilensky G.R. Cost-effectiveness information: Yes, it's important, but keep it separate, please!. Annals of Internal Medicine 2008, 148(12):967-968.